Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

847 results about "Mutant protein" patented technology

A mutant protein is the protein product encoded by a gene with mutation. Mutated protein can have single amino acid change (minor, but still in many cases significant change leading to disease) or wide-range amino acid changes by e.g. truncation of C-terminus after introducing premature stop codon.

Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant KRAS useful for the treatment of cancer

This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins, including KRAS G12D. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.
Owner:JAZZ PHARMA IRELAND LTD +6

Quinazoline compound and use thereof

A quinazoline compound and a use thereof. The quinazoline compound is shown in formula (I). The quinazoline compound has a good inhibitory effect on a KRAS G12D mutant protein, and has good prospects for drug development.
Owner:SHANGHAI PHARMACEUTICALS HOLDING CO LTD

Preparation and use of pyrimidothiopyranone kras mutant protein inhibitor

The present invention relates to a KRASG12D inhibitor and the use thereof. Specifically, provided in the present invention is a compound as shown in formula (I), and the definition of each substituent in the formula is as described in the description. In addition, the present invention further relates to a composition containing the inhibitor and the use thereof. The compound of the present invention has good tumor growth inhibitory activity, and has good safety.
Owner:YAOYA TECH SHANGHAI CO LTD

Antibody-drug conjugate containing heterocyclic compound having activity of inducing decomposition of KRAS mutant proteins

Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate. The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.
Owner:ASTELLAS PHARMA INC

Mutant protein screening method and device and related equipment

The invention discloses a mutant protein screening method and device and related equipment thereof, and relates to the technical field of material determination and analysis. The method comprises the following steps: respectively carrying out simulated single mutation on a plurality of amino acid sites in a protein sequence of a target protein to obtain a plurality of simulated mutant proteins, and determining adaptability evaluation values F of the plurality of simulated mutant proteins based on a target protein language model; determining structural stability values S of the plurality of simulated mutant proteins based on a protein folding energy calculation tool; performing normalization processing on the adaptability evaluation value F and the structural stability value S, and performing single-index sorting and comprehensive-index sorting on normalization processing results; and screening the plurality of simulated mutant proteins according to the target screening number, the single index sorting result and the comprehensive index sorting result to obtain a target mutant protein. According to the method, the protein design transformation difficulty can be reduced, the mutant protein screening effect is improved, the calculation amount required by protein transformation and screening is reduced, and the consumption cost is reduced.
Owner:CIXI INST OF BIOMEDICAL ENG NINGBO INST OF IND TECH CHINESE ACAD OF SCI NINGBO +1

High-activity high-thermal-stability MHET hydrolase mutant and application thereof

The invention discloses a high-activity and high-thermal-stability MHET hydrolase mutant and application thereof. The invention provides a mutant protein of thermophilic carboxylesterase, which is shown as 1) or 2): 1) the protein shown as 1) is a protein obtained by mutating amino acid residues at the 130th site and the 171th site of wild thermophilic carboxylesterase shown as SEQ ID NO.2 or a sequence corresponding to the SEQ ID NO.2 and keeping other amino acid residues unchanged; (2) the protein is obtained by mutating amino acid residues at the 127th site, the 130th site and the 171th site of wild thermophilic carboxylesterase and keeping other amino acid residues unchanged. Experiments prove that the activity of the modified mutant for catalyzing MHET hydrolysis at the temperature of 50 DEG C is improved by 95 times compared with that of a wild type, and the modified mutant has higher enzyme activity and thermal stability and is the first enzyme capable of efficiently catalyzing MHET hydrolysis at the temperature of 50 DEG C at present.
Owner:BEIJING UNIV OF CHEM TECH

Multifunctional molecules that bind to calreticulin and uses thereof

Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and / or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Owner:MARENGO THERAPEUTICS INC

P53-y220c selective small-molecular reactivator compound, pharmaceutical composition and use thereof

PCT designated stage expiredWO2025002177A1Organic active ingredientsOrganic chemistryDiseaseEster prodrug
Provided in the present invention are compounds shown as formula (I) and racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts thereof, which have good p53-Y220C mutant activation effect, can be used for treating tumor diseases containing p53-Y220C mutant proteins, and can be used for preparing drugs for such disorders or diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Tethered spiro-heterocyclic inhibitors of KRAS g12c mutant proteins and uses thereof

The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung cancer, pancreatic cancer, colorectal cancer, and solid tumors. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described.
Owner:AMGEN INC

Iscb mutein and use thereof

PCT designated stage expiredWO2025138738A1HydrolasesForeign genetic material cellsBiotechnologyArginine
The present invention belongs to the technical field of bioengineering. Provided are an IscB mutein and the use thereof. Compared to the wild-type IscB protein, the IscB mutein comprises arginine at at least one of the following amino acid positions: position 84, position 96, position 102, position 111, position 159, position 368 and position 386; preferably, the IscB mutein further comprises arginine at position 401 and position 456. The relatively strong interaction between the IscB mutein and a double-stranded DNA target improves the editing activity for mammalian cell lines, which can greatly enhance the application potential of the IscB mutein as a new-generation underlying tool for gene editing, and promote the use of the IscB mutein in the aspects of precision medicine, animal model construction and crop breeding.
Owner:EAST CHINA NORMAL UNIV +1

Optimized NlovFz2-omega RNA editing system

The invention discloses an optimized NlovFz2-omega RNA (Ribonucleic Acid) editing system, the optimal NlovFz2 system enNlovFz2 is obtained by modifying NlovFz2 protein and an omega RNA skeleton, and on the basis of remarkably improving the editing efficiency compared with a parent NlovFz2 system, the NlovFz2 mutant protein and T5 exonuclease are fused to obtain an enNlovFz2-T5 system with higher editing efficiency. The method has important significance and value for promoting wide application of a gene editing technology in the aspects of functional mechanism research and clinical treatment.
Owner:NORTHWEST A & F UNIV

P53-Y220C selective small-molecule reactivator compound, pharmaceutical composition and application of p53-Y220C selective small-molecule reactivator compound

The invention provides a compound as shown in a formula (I), and a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof. The compound has a good p53-Y220C mutant activation effect, can effectively recover the activity of the p53-Y220C mutant protein, and is used for treating tumor diseases containing the p53-Y220C mutant protein and preparing drugs for the diseases or the diseases. # imgabs0 #
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Graph convolution networks to identify and quantify gene and cancer specific transcriptome signatures of cancer driver events

This disclosure describes a Machine Learning (ML) framework, including graph convolution neural networks (GCN) for identifying gene expression signatures related to cancer driver events. The model is trained to identify the TP53 mutational state of cancer samples from gene expression, utilizing comprehensive curated graph structures of gene interactions. A quantitative score is generated to rank the severity of a driver event in each sample. Very high AUG results on unseen data across several tumor types are achieved with this method. There is a strong correlation with protein function. The Signatures in Transcriptome Associated with Mutated Protein (STAMP) model can also predict driver events in many combinations of important cancer genes / pathways and several tumor types, based on well-established annotations from the literature. The STAMP model therefore can identify and quantify driver events, which may lead the way to improved targeted therapy selection and prioritization in cancer patients.
Owner:HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD

High-activity PET hydrolase mutant and application thereof

The invention belongs to the field of biological catalysis, and discloses a high-activity PET hydrolase mutant and application thereof. The mutant of the thermophilic PET hydrolase provided by the invention is as shown in 1), 2) or 3): 1) a protein corresponding to an amino acid sequence SEQ ID NO.4; 2) a protein corresponding to the amino acid sequence of SEQ ID NO.6; and 3) a protein corresponding to the amino acid sequence of SEQ ID NO.8. Experiments prove that the modified mutant shows higher catalytic efficiency on PET hydrolysis and can keep activity for a long time at the optimal temperature for PET depolymerization. The activity of the mutant protein BhrM3 for catalyzing PET hydrolysis is improved by 1.82 times compared with that of a wild type and is 1.22 times that of efficient PET hydrolase LCC-ICCG, and the protein melting temperature reaches 92.9 DEG C.
Owner:BEIJING UNIV OF CHEM TECH

Cas protein having improved activity and use thereof

PCT designated stage expiredWO2025108148A1HydrolasesFermentationMutated proteinWild type
The present invention belongs to the field of nucleic acid editing, and particularly the technical field of clustered regularly interspaced short palindromic repeats (CRISPRs). Specifically, provided in the present invention is a Cas mutant protein having an improved activity and an improved editing efficiency. Compared with a wild-type parental Cas protein, the Cas mutant protein of the present invention has significantly improved activity, and has a wide application prospect.
Owner:SHANDONG SHUNFENG BIOTECH CO LTD

L-histidine transporter mutant and method for increasing yield of L-histidine

The invention discloses an L-histidine transporter mutant and a method for increasing the yield of L-histidine, and the mutant has any one mutation of I20A, V28L, I20A-V28L and I20A-V21L-T28S relative to an escherichia coli wild type yeaS. The yield of the L-histidine of the recombinant escherichia coli containing the yeaS mutant protein is remarkably increased, it is indicated that the yeaS mutant protein and the coding gene of the yeaS mutant protein can be used for increasing the yield of the L-histidine, and the mutant can lay a good foundation for industrial efficient production of the L-histidine and downstream metabolites.
Owner:ANHUI HUAHENG BIOTECH CO LTD +2

Molecular modification method for glycosyltransferase based on artificial intelligence

The invention provides a molecular modification method for glycosyltransferase based on artificial intelligence. The method comprises the following steps: acquiring description information of enzyme mutants to form a basic data set; performing physicochemical property analysis on the basic data set to obtain an analysis result set; calculating the quantized value of the conservative degree of the mutation site and the quantized value of the influence degree of different mutations on the sequence so as to construct a position specificity scoring matrix; extracting a position specificity scoring value and a frequency from the scoring matrix, determining a functional section, and performing weighting processing; performing three-dimensional structure prediction and energy calculation based on the three-dimensional structure reconstruction model of the mutant to obtain an energy value; calculating an energy change value between the mutant and the wild type; performing molecular docking and dynamic simulation analysis on the mutant protein to obtain quantitative description of an interaction mode and strength and dynamic simulation characteristic data; and constructing a model training set to train a machine learning model for predicting the change of the enzyme activity of the mutant.
Owner:BEIJING QINGKE BIOTECHNOLOGY CO LTD

Ochratoxin A degrading enzyme mutant and application thereof

The invention discloses an ochratoxin A degrading enzyme mutant and application thereof. The invention provides mutant protein of amidase MiADH, which is any one of the following changes: the amino acid sequence of the amidase MiADH as shown in SEQ ID NO: 1 is subjected to any one of the following changes: a 66th amino acid residue Y is mutated into K, or a 143rd amino acid residue H is mutated into A, or a 194th amino acid residue V is mutated into A, or a 195th amino acid residue L is mutated into A, or a 230th amino acid residue H is mutated into A, or the amino acid sequence of the amidase MiADH is mutated into A, or the amino acid sequence of the amidase MiADH is mutated into K, or the amino acid sequence of the amidase MiADH is mutated into A; or the 324th amino acid residue V is mutated into A, and the protein has the same function; experiments prove that the amide hydrolase MiADH mutant can efficiently degrade OTA, and OTA detoxification can be achieved under the high-temperature condition.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Method and system for predicting neoantigen of malignant solid tumor

The invention relates to the technical field of tumor neoantigen detection, and particularly discloses a neoantigen prediction method and system for a malignant solid tumor, and the method comprises the following steps: obtaining a tumor sample and a peripheral blood sample, and carrying out DNA and RNA sequencing; analyzing and processing to obtain DNA (Deoxyribonucleic Acid) sequencing data and RNA (Ribonucleic Acid) sequencing data; analyzing to obtain an HLA typing result and a sequence of the mutant protein; calculating to obtain related characteristic values of the new antigens; calculating a new antigen score; and intercepting the first N pieces with the highest scores to obtain a neoantigen prediction result of the malignant solid tumor. Starting from the action mechanism of the new antigens, according to key steps of the prediction process, a plurality of characteristic values are selected, a hard filtering index is not adopted, a product mode is adopted, and the score of the new antigens is calculated according to the score of the relevant characteristic values of the new antigens.
Owner:TIANJIN CANCER HOSPITAL AIRPORT HOSPITAL

Protein stability prediction method and device, computer equipment and storage medium

The embodiment of the invention provides a protein stability prediction method and device, computer equipment and a storage medium. The method comprises the following steps: acquiring a first to-be-detected sequence corresponding to an original protein and a second to-be-detected sequence corresponding to a mutant protein; determining a plurality of first target residue features from the first to-be-detected sequence according to an attention mechanism of a protein language model, and extracting global features of the first target residue features to obtain first virtual structure microenvironment features; similarly, obtaining second virtual structure microenvironment features corresponding to a plurality of second target residue features; determining a first difference value based on the first virtual structure microenvironment feature and the second virtual structure microenvironment feature, and determining a second difference value based on a first global sequence feature corresponding to the first to-be-detected sequence and a second global sequence feature corresponding to the second to-be-detected sequence; and performing prediction according to the first difference value and the second difference value to obtain a protein stability prediction result. Therefore, the accuracy of predicting the stability of the protein can be improved.
Owner:PENG CHENG LAB

Nitrilase and application thereof in preparation of p-cyanobenzoic acid

The invention provides a nitrilase mutant and application of the nitrilase mutant in synthesis of p-cyanobenzoic acid. The invention provides a nitrilase mutant capable of improving the activity of catalytic synthesis of p-cyanobenzoic acid, the mutant protein is a non-natural protein, and the mutant protein can significantly improve the activity of catalyzing p-phthalonitrile to generate p-cyanobenzoic acid. And the mutant protein mutates in two or more core amino acids related to enzyme catalytic activity of the wild nitrilase. The nitrilase mutant provided by the invention can significantly improve the yield of a nitrilase catalytic synthesis product.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Mutant protein of dihydroxyacetone phosphate phosphatase and application

The invention discloses mutant protein of dihydroxyacetone phosphate phosphatase and application of the mutant protein. The invention provides a phosphodihydroxyacetone phosphatase mutant protein, which is characterized in that residues of phosphodihydroxyacetone phosphatase corresponding to 21st, 36th, 42nd, 49th, 64th, 82nd, 150th and 244th sites of an amino acid sequence shown in a sequence 1 are mutated to obtain a protein with phosphodihydroxyacetone phosphatase activity; and the synthesis capability of the 1, 3-dihydroxyacetone is improved. The invention also provides related biological materials and derivatives of the protein, and application of the protein in preparation of 1, 3-dihydroxyacetone. The yield of 1, 3-dihydroxy acetone of the protein is greatly increased, compared with starting wild type dihydroxy acetone phosphate phosphatase, the yield of 1, 3-dihydroxy acetone obtained through shake flask fermentation of the dihydroxy acetone phosphate phosphatase mutant SF6-11 is increased by 1.65 times, and the yield of 1, 3-dihydroxy acetone is increased to 4.54 + / -0.09 g / L from 2.75 + / -0.07 g / L.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Cas12j protein with improved editing activity and application thereof

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, the invention provides a Cas12j mutant protein with improved editing activity and application thereof, and the Cas12j mutant protein has a wide application prospect.
Owner:SHANDONG SHUNFENG BIOTECH CO LTD

Mutated Cas protein and application thereof

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, the invention provides a Cas mutant protein with improved activity and improved editing efficiency, and compared with a wild parent Cas protein, the Cas mutant protein disclosed by the invention has the advantages that the activity is obviously improved, and the Cas mutant protein has a wide application prospect.
Owner:SHANDONG SHUNFENG BIOTECH CO LTD

PGK-C-A protein for improving yield of nostoc flagelliforme polysaccharide, method and application

The invention belongs to the technical field of industrial microorganisms, and discloses a PGK-C-A mutant protein modified through point mutation, and the amino acid sequence of the mutant protein is SEQ ID NO. 1. According to the invention, amino acid residues subjected to glutathione modification in PGK protein are replaced by heterologous expression and point mutation methods to obtain PGK mutant protein with reduced enzyme activity, and the PGK mutant protein is named as PGK-C-A; the enzyme activity is reduced relative to the original PGK protein, so that the nostoc flagelliforme polysaccharide yield is increased.
Owner:TIANJIN UNIV OF SCI & TECH

Carbonyl reductase mutant and application thereof in synthesis of S-glassine

The invention provides a carbonyl reductase mutant and an application of the carbonyl reductase mutant in synthesis of S-glassine. The mutant protein is a non-natural protein, and the mutant protein can significantly improve the activity of catalyzing the reduction of carbonyl in 1-C-(beta-D-xylopyranosyl)-acetone to generate S-configuration alcohol. When the activity-improved carbonyl reductase mutant strain is applied to the production process of S-configuration glassine, the carbonyl reduction capacity of the S-configuration glassine can be improved, 100-240 g / L of substrate can be completely converted, and the S-configuration glassine is generated.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Daptomycin high-yield engineering strain with high capric acid tolerance as well as construction and application of daptomycin high-yield engineering strain

The invention discloses a daptomycin high-yield engineering strain with high capric acid tolerance as well as construction and application of the daptomycin high-yield engineering strain. According to the invention, a DptE mutant protein is obtained through amino acid mutation on the basis of a DptE protein, and the DptE mutant protein comprises one of a DptE mutant protein DptE:: K454I, a DptE mutant protein DptE:: K454R and a DptE mutant protein DptE:: K454I: Q420N: K184Q; according to the invention, a DptE protein coding gene in streptomyces roseosporus is replaced by a DptE mutant protein coding gene, and a TagR protein coding gene is knocked out, so that a daptomycin high-yield engineering strain is constructed. According to the method, the defects of long cycle and large manpower and material resource consumption of traditional mutation breeding are overcome, the production cost of daptomycin is greatly reduced, and the method has important application value in the industrial production process.
Owner:ZHEJIANG UNIV

Pfago mutant protein having target nucleic acid cleavage activity at medium temperatures and use thereof

Provided are a PfAgo mutant protein having target nucleic acid cleavage activity at medium temperatures and a use thereof. The PfAgo mutant protein has an amino acid mutation at position 617 and / or position 618 relative to the sequence as shown in SEQ ID NO. 1, specifically, K617E / G and / or L618Y / F / W / G. Compared with a wild-type PfAgo protein, the provided PfAgo mutant protein has activity in a temperature range of 30-95°C, and thus, the scope of use of the pAgo protein is effectively expanded.
Owner:HUBEI UNIV

Wheat mutant protein with glyphosate resistance, gene and application thereof

The invention discloses a wheat mutant protein with glyphosate resistance, a gene and application thereof, and belongs to the technical field of plant breeding. The invention discloses wheat mutant proteins GR1 and GR19 with glyphosate resistance, six mutation sites and three mutation sites exist on an ESPSP protein respectively, and amino acid sequences of the 128 to 308 sites and amino acid sequences of the 133 to 308 sites are shown as SEQ ID NO. 4 and SEQ ID NO. 5 respectively. Two mutants with glyphosate resistance and excellent agronomic traits are found in a wheat mutant group by taking glyphosate as a screening agent, the two mutants are named as common wheat ZM9-GR1 and common wheat ZM9-GR19, and the invention discloses application of the mutants in plant breeding. The invention also discloses a method for cultivating glyphosate-resistant wheat by using the mutant for backcross breeding and cross breeding. The invention has important application value in plant breeding and agricultural production.
Owner:NANTONG XINDAO BREEDING TECH CO LTD